1. CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE. (9th November 2020) Authors: Ahluwalia, Manmeet; Peereboom, David; Rauf, Yasmeen; Schilero, Cathy; Ciolfi, Marci; Ciesielski, Michael; Fenstermaker, Robert Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM). (9th November 2020) Authors: Ahluwalia, Manmeet; Peereboom, David; Rauf, Yasmeen; Lathia, Justin; Alban, Tyler; Schilero, Cathy; Ciolfi, Marci; LaForest-Roys, Corey; Nayak, Lakshmi; Lee, Eudocia; Wen, Patrick; Reardon, David Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗